Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Centene's First-Quarter Surge: Sales Soar To $40.41B, Exceeding Expectations: What's Next For The Healthcare Company?

Published 26/04/2024, 15:20
© Reuters.  Centene's First-Quarter Surge: Sales Soar To $40.41B, Exceeding Expectations: What's Next For The Healthcare Company?

Benzinga - by Vandana Singh, Benzinga Editor.

Centene Corporation (NYSE:CNC) reported first-quarter sales of $40.41 billion, up 11% Y/Y, beating the consensus of $36.14 billion.

Premium and service revenues increased 4% to $36.3 billion, driven by membership growth in the Marketplace business due to strong product positioning and overall market growth, partially offset by recent divestitures in the Other segment and lower Medicaid membership primarily due to redeterminations.

The health benefits ratio of 87.1% for the first quarter of 2024 represented an increase from 87.0% in the comparable period in 2023.

Related: See How Florida’s Much Awaited Medicaid Re-Procurement Awards Impact Centene, Humana, Molina.

The company reported a first-quarter adjusted EPS of $2.26, up from $2.11 a year ago, beating the consensus of $2.08.

“Centene’s first quarter results demonstrate the strength of our diversified platform,” Centene CEO Sarah London said in a statement accompanying the company’s earnings report. “We are pleased to raise full-year 2024 guidance as we look to maximize the positive momentum being generated by our core businesses.”

Centene said total managed care membership held steady at 28.42 million at the end of the first quarter of this year, compared to 28.45 million a year ago.

Centene’s enrollment in its “commercial marketplace” business grew to 4.3 million members from 3 million a year ago.

Premium revenues from Commercial business increased 48% Y/Y to $7.8 billion.

Total Medicaid memberships fell over 18% to 13.3 million from 16.3 million.

Guidance: Centene revised its 2024 adjusted EPS guidance floor of greater than $6.80 versus prior guidance of greater than $6.70 versus consensus of $6.78.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Centene expected 2024 revenue guidance of $147.5 billion-$150.5 billion versus the consensus Of $146.14 billion, including premium and service revenues of $135.5 billion-$138.5 billion versus prior guidance of $134.5 billion-$137.5 billion.

CNC Price Action: Centine shares are down 4.11% at $72.57 at publication Friday.

Read Next: Fed’s Key Inflation Indicator Hits 2.8%, Dashes Rate Cut Hopes; Traders On Alert

Photo: Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.